Skip to main content

ravulizumab (UltomirisĀ®)

 

Status: In progress

For the treatment of paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH): 

  • in patients with haemolysis with clinical symptom(s) indicative of high disease activity
  • in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months

Medicine details

Medicine name ravulizumab (UltomirisĀ®)
Formulation 300 mg/3 mL concentrate for solution for infusion, 1,100 mg/11 mL concentrate for solution for infusion
Reference number 4869
Indication

As above

Company Alexion Pharma UK Ltd
BNF chapter Nutrition & blood
Submission type Licence extension for paediatric use
Status In progress
AWMSG meeting date 09/02/2022
Date of issue TBC